CIRCULATING INTERLEUKIN-10 AND INTERLEUKIN-6 SERUM LEVELS IN RHEUMATOID-ARTHRITIS PATIENTS TREATED WITH METHOTREXATE OR GOLD SALTS - PRELIMINARY-REPORT
CIRCULATING INTERLEUKIN-10 AND INTERLEUKIN-6 SERUM LEVELS IN RHEUMATOID-ARTHRITIS PATIENTS TREATED WITH METHOTREXATE OR GOLD SALTS - PRELIMINARY-REPORT
复制标题
DOI：
10.1007/bf01630483
复制
发表时间：
1995-01-01
影响因子：
6.7
通讯作者：
MULLER, W
中科院分区：
文献类型：
--
作者：
LACKI, JK;KLAMA, K;MULLER, W
为了评估接受甲氨蝶呤 (MTX) 或肌注金 (IMG) 治疗的类风湿关节炎 (RA) 患者血清中白介素 10 (IL-10)、IL-6 和急性期蛋白浓度之间的关系，我们测定了患者血清中的 IL-10、IL-6、C 反应蛋白 (CRP)、α-1-酸性糖蛋白 (AGP) 和 α-1-抗胰凝乳蛋白酶 (ACT)。 35 名 RA 患者。使用酶联免疫测定 (ELISA) 评估 IL-10 和 IL-6 水平。使用火箭免疫电泳测量 AGP 和 ACT 水平。与对照组相比，RA 患者的 IL-10 血清水平没有增加（58.7 +/- 18.1 pg/ml vs. 57.2 +/- 11.9 pg/ml）。 IL-6 水平显着升高（91.6 +/- 46.9 pg/ml 对比 45 +/- 19 pg/ml，p < 0.05）。与健康对照相比，CRP 显着升高（35 +/- 19 mg/l vs. 3 +/- 2 mg/l，p < 0.05）。与仅接受 NSAID 治疗的患者相比，接受 MTX 或 IMG 治疗的患者的 IL-10 水平升高，IL-6 含量降低。然而，只有接受 IMG 和 NSAID 治疗的患者之间的变化才被发现具有统计学意义。发现 IL-10 和 IL-6 血清水平之间存在良好的负相关性（r = -0.75，p < 0.05）。 IL-6血清水平与CRP（r = 0.62，p < 0.05）、AGP（r = 0.78，p < 0.05）和ACT（r = 0.45，p < 0.05）之间存在显着正相关。另一方面，IL-10与血清CRP水平（r = -0.76，p < 0.05）、AGP（r = -0.64，p < 0.05）和ACT（r = -0.38，p < 0.05）之间也观察到负相关。此外，当对接受 MTX、IMG 或 NSAID 治疗的患者进行独立分析时，这些关系仍然存在。根据迄今为止获得的数据，IL-10似乎减少了IL-6的产生，从而间接影响了急性期反应，降低了RA患者的CRP、AGP和ACT浓度。
In order to evaluate the relationship between serum concentrations of interleukin-10 (IL-10), IL-6, and acute phase proteins in rheumatoid arthritis (RA) patients treated with methotrexate (MTX) or intramuscular gold (IMG) we determined IL-10, IL-6, C-reactive protein (CRP), alpha-1-acid glycoprotein (AGP) and alpha-1-antichymotrypsin (ACT) in the sera of 35 RA patients. IL-10 and IL-6 levels were evaluated using an enzyme-linked immunoassay (ELISA). AGP and ACT level were measured using rocket immunoelectrophoresis. IL-10 serum level was not increased in RA patients as compared to controls (58.7 +/- 18.1 pg/ml vs. 57.2 +/- 11.9 pg/ml). IL-6 level was significantly elevated (91.6 +/- 46.9 pg/ml vs. 45 +/- 19 pg/ml, p < 0.05). CRP was significantly increased as compared to healthy controls (35 +/- 19 mg/l vs. 3 +/- 2 mg/l, p < 0.05). Patients treated with MTX or IMG presented an increased level of IL-10 and decreased amounts of IL-6, as compared to those treated with NSAID only. However, only changes between patients treated with IMG and NSAID were found to be statistically significant. A good negative correlation between IL-10 and IL-6 serum level was found (r = -0.75, p < 0.05). A positive significant correlation between IL-6 serum level and CRP (r = 0.62, p < 0.05), AGP (r = 0.78, p < 0.05) and ACT (r = 0.45, p < 0.05) was established. On the other hand, a negative correlation between IL-10 and serum level of CRP (r = -0.76, p < 0.05), AGP (r = -0.64, p < 0.05) and ACT (r = -0.38, p < 0.05) was also observed. Moreover, these relationships were maintained when patients treated with MTX, IMG, or NSAID were analyzed independently. According to the data thus far obtained, it seems that IL-10 decreases IL-6 production, and thereby indirectly affects the acute phase response, decreasing CRP, AGP, and ACT concentration in RA patients.